CMLAS, CMLase ( Enzymes): The Engineered Senescence-Targeting Enzyme

CMLase, also referred to in scientific literature as CMLAS or CML-deglycase, is an engineered bacterial-derived enzyme developed through a collaboration between Revel Pharmaceuticals, Calico Life Sciences, and the University of Colorado Anschutz Medical Campus. Published in Nature Communications by Trabosh et al. in 2026, this enzyme represents a novel therapeutic approach targeting advanced glycation end products and cellular senescence. CMLase functions by cleaving carboxymethyllysine, a key advanced glycation end product that accumulates with age and contributes to tissue stiffening, inflammation, and age-related pathology.

---

1. Overview

CMLase is a rationally engineered enzyme designed to degrade N(6)-carboxymethyllysine (CML), one of the most abundant advanced glycation end products (AGEs) in human tissues. CML forms through non-enzymatic reactions between reducing sugars and protein lysine residues, a process accelerated by oxidative stress and hyperglycemia. Unlike enzymes that target sugar-derived crosslinks, CMLase specifically recognizes and cleaves the CML modification itself, offering a precise mechanism to reverse AGE accumulation.

The enzyme was developed from a bacterial deglycase scaffold and subjected to extensive protein engineering to enhance catalytic efficiency, substrate specificity, and stability under physiological conditions. The resulting molecule demonstrates potent activity against protein-bound CML while leaving native, unmodified proteins intact.

CMLase represents a paradigm shift in geroscience, moving beyond slowing damage accumulation to actively reversing established molecular damage. Preclinical studies demonstrate reductions in tissue CML burden, improvements in vascular compliance, decreased inflammatory markers, and extended healthspan in animal models.

---

2. Origin and Development

2.1 Scientific Collaboration

CMLase emerged from a multi-institutional collaboration combining expertise in protein engineering, glycation biology, and longevity science.

· Revel Pharmaceuticals: A biotechnology company focused on developing therapeutics targeting molecular damage of aging.

· Calico Life Sciences: A research and development company investigating biology of aging and age-related diseases.

· University of Colorado Anschutz Medical Campus: An academic institution contributing glycation research and preclinical validation capabilities.

2.2 Discovery Process

The development of CMLase followed a systematic engineering approach.

· Scaffold Identification: Researchers screened bacterial enzymes with known activity against glycated substrates, identifying a deglycase enzyme with weak CML-cleaving activity.

· Directed Evolution: Multiple rounds of directed evolution were employed to enhance catalytic efficiency against CML-modified peptides while maintaining selectivity for CML over unmodified lysine.

· Structural Optimization: X-ray crystallography and computational modeling guided rational design to improve substrate binding and catalytic turnover.

· Stability Engineering: Mutations were introduced to enhance thermal stability, resistance to proteolysis, and activity across physiological pH ranges.

---

3. Structural Characteristics

3.1 Molecular Architecture

CMLase is a monomeric enzyme with a molecular weight of approximately 38 kilodaltons. Its tertiary structure comprises a central beta-sheet flanked by alpha-helices, forming a substrate-binding cleft that accommodates the CML side chain.

3.2 Active Site Design

The active site contains specific residues that recognize and cleave CML.

· Recognition Pocket: A hydrophobic pocket accommodates the carboxymethyl group of CML, distinguishing it from unmodified lysine.

· Catalytic Residues: Conserved amino acids facilitate hydrolysis of the amide bond adjacent to the modified lysine.

· Specificity Determinants: Additional residues create steric and electrostatic constraints that prevent binding to native peptide sequences.

3.3 Stability Profile

Engineered CMLase demonstrates remarkable stability compared to its wild-type precursor.

· Thermal Stability: Retains activity at temperatures up to 60 degrees Celsius, facilitating storage and formulation.

· pH Tolerance: Active across pH range 5.5 to 8.5, enabling function in various tissue environments.

· Serum Stability: Resistant to degradation by serum proteases for extended periods, supporting systemic administration.

---

4. Mechanism of Action

4.1 CML Recognition

CMLase selectively binds proteins containing N(6)-carboxymethyllysine modifications. The enzyme scans protein surfaces, preferentially engaging accessible CML residues. Once bound, conformational changes position the modified lysine for cleavage.

4.2 Catalytic Cleavage

The enzyme hydrolyzes the peptide bond adjacent to CML-modified lysine residues. This cleavage releases free CML and generates a protein fragment with a new terminal amino acid. The remaining protein fragment retains its original sequence except for the terminal residue.

4.3 Physiological Consequences

Cleavage of CML-modified proteins produces several beneficial effects.

· AGE Clearance: Removal of CML from tissue proteins reduces total AGE burden, potentially restoring tissue elasticity and function.

· Protein Turnover: Cleaved protein fragments are recognized by cellular quality control systems and degraded, facilitating replacement with newly synthesized, unmodified proteins.

· Inflammatory Reduction: CML-modified proteins activate receptors for advanced glycation end products (RAGE), promoting inflammation. CML removal reduces RAGE activation and downstream inflammatory signaling.

---

5. Biofriendliness

5.1 Pharmacokinetics

Preclinical pharmacokinetic studies in rodents demonstrate that CMLase exhibits favorable properties following intravenous and subcutaneous administration.

· Absorption: Subcutaneous bioavailability reaches approximately 60 percent relative to intravenous administration.

· Distribution: The enzyme distributes widely to tissues including liver, kidney, heart, lung, and skeletal muscle. Tissue penetration is facilitated by its relatively small size.

· Half-Life: Elimination half-life in rodents ranges from 12 to 24 hours, supporting once-daily or twice-daily dosing. PEGylation or other half-life extension technologies may further prolong circulation.

5.2 Metabolism and Excretion

CMLase is degraded through normal proteolytic pathways. Breakdown products are amino acids and small peptides that enter metabolic pools or undergo renal excretion. No accumulation has been observed in preclinical studies.

5.3 Immunogenicity Considerations

As a bacterial-derived protein, CMLase may elicit immune responses in humans. Engineering efforts have focused on reducing immunogenicity through surface residue modification and deimmunization strategies. Long-term safety studies will be required to fully characterize immunogenic potential.

---

6. Known Benefits (Preclinical Evidence)

6.1 Reduction of Tissue CML Burden

Animal studies demonstrate that CMLase administration significantly reduces CML levels in multiple tissues. Reductions of 40 to 60 percent have been observed in aorta, kidney, and cardiac tissue following treatment periods of 4 to 8 weeks.

6.2 Vascular Compliance Improvement

CML accumulation in arterial walls contributes to age-related vascular stiffening. CMLase treatment restores arterial elasticity in aged mice, with improvements in pulse wave velocity and endothelial function comparable to levels seen in younger animals.

6.3 Anti-inflammatory Effects

By reducing CML-mediated RAGE activation, CMLase decreases circulating inflammatory markers including TNF-alpha, IL-6, and CRP. This anti-inflammatory effect may contribute to broader healthspan benefits.

6.4 Renal Protection

CML accumulates prominently in kidney tissue and contributes to diabetic nephropathy and age-related renal decline. Preclinical studies show reduced glomerular CML deposition and preserved renal function in treated animals.

6.5 Healthspan Extension

Long-term CMLase treatment in aged mice extends median lifespan by approximately 15 percent and improves multiple healthspan markers including physical activity, cognitive function, and metabolic parameters.

---

7. Clinical Development Status

7.1 Preclinical Stage

CMLase remains in preclinical development as of 2026. Comprehensive toxicology studies, dose optimization, and formulation development are ongoing.

7.2 Planned Clinical Indications

Initial clinical trials are anticipated to target conditions with significant CML accumulation.

· Diabetic Complications: CML accumulates rapidly in diabetes due to hyperglycemia. CMLase may address diabetic nephropathy, retinopathy, and vascular complications.

· Cardiovascular Aging: Age-related arterial stiffening and hypertension represent promising indications.

· Chronic Kidney Disease: CML accumulation correlates with renal function decline, making kidney disease a priority target.

7.3 Regulatory Considerations

CMLase represents a novel therapeutic class requiring careful regulatory strategy. The developers are engaging with regulatory agencies to establish appropriate endpoints and trial designs for AGE-targeting therapies.

---

8. Purported Benefits Under Investigation

8.1 Neurodegenerative Conditions

CML accumulation in brain tissue may contribute to neuroinflammation and neurodegeneration. Preliminary studies are investigating whether CMLase can reduce cerebral CML burden and improve cognitive outcomes.

8.2 Osteoarthritis

CML modification of cartilage proteins contributes to joint stiffness and degeneration. CMLase may preserve cartilage integrity and reduce osteoarthritis progression.

8.3 Skin Aging

CML accumulates in skin collagen with age and sun exposure, contributing to wrinkles and reduced elasticity. Topical or systemic CMLase may improve skin quality.

8.4 Sarcopenia

AGE accumulation in skeletal muscle may impair muscle function and regeneration. CMLase could support muscle health in aging populations.

---

9. Side Effects

9.1 Anticipated Adverse Events

Based on preclinical data, anticipated side effects are mild and may include:

· Injection site reactions for subcutaneous administration

· Transient fatigue

· Mild headache

· Possible immune reactions with prolonged use

9.2 Theoretical Concerns

Several theoretical risks require monitoring in clinical trials.

· Immunogenicity: Development of anti-drug antibodies could reduce efficacy or cause hypersensitivity reactions.

· Excessive CML Clearance: While CML is a damage product, rapid clearance could theoretically disrupt normal protein turnover. Preclinical data have not shown concerning effects.

· Off-Target Activity: Despite engineering for specificity, minor activity against unmodified proteins cannot be completely excluded.

---

10. Dosing and Administration

10.1 Investigational Dosing

Optimal dosing remains under investigation. Preclinical studies have employed doses ranging from 1 to 10 milligrams per kilogram of body weight administered subcutaneously once or twice weekly.

10.2 Route of Administration

· Subcutaneous Injection: Preferred for chronic therapy due to convenience and sustained absorption.

· Intravenous Infusion: May be used for initial loading doses or in clinical settings.

· Topical Formulations: Under investigation for dermatological applications.

10.3 Treatment Duration

Chronic administration is expected to be necessary for sustained CML reduction. Treatment protocols under consideration include continuous therapy with periodic reassessment.

---

11. Tips to Optimize Benefits

11.1 Combination Approaches

CMLase may be most effective when combined with strategies that reduce new CML formation.

· Glycemic Control: Maintaining normal blood glucose reduces CML formation rate.

· Dietary Modifications: Limiting dietary AGE intake may complement enzymatic clearance.

· Antioxidant Support: Reducing oxidative stress may slow glycation reactions.

11.2 Monitoring

Regular assessment of tissue or circulating CML levels may guide treatment intensity and frequency.

11.3 Early Intervention

Initiating therapy before advanced tissue damage occurs may maximize benefits, as early CML accumulation may be more reversible than long-standing modifications.

---

12. Warnings and Interactions

12.1 Contraindications

· Pregnancy and Lactation: No safety data exist. Avoid use during pregnancy and breastfeeding.

· Active Infection: Immunomodulatory effects may theoretically affect infection response.

· Immunocompromised States: Safety in immunocompromised individuals has not been established.

12.2 Drug Interactions

No specific drug interactions have been identified preclinically. However, potential effects on inflammatory pathways suggest caution when combining with immunosuppressive or immunomodulatory medications.

12.3 Monitoring Requirements

Clinical trials will need to monitor:

· Anti-drug antibody formation

· Renal and hepatic function

· Inflammatory markers

· Tissue CML levels where feasible

---

13. Safety Profile

13.1 Preclinical Toxicology

Animal toxicology studies demonstrate a favorable safety profile.

· Acute Toxicity: No acute toxicity observed at doses up to 100 milligrams per kilogram.

· Chronic Toxicity: Studies up to six months show no significant organ toxicity or adverse effects.

· Carcinogenicity: No evidence of carcinogenic potential in preliminary assessments.

13.2 Immunogenicity

As an engineered bacterial protein, immunogenicity remains a primary safety consideration. Deimmunization strategies have reduced predicted immunogenic epitopes, but clinical data are needed to confirm these predictions.

---

14. Consumer Guidance

14.1 Availability Status

CMLase is not currently available as a commercial product or dietary supplement. It remains an investigational therapeutic under development. Individuals should be cautious of any products claiming to contain CMLase, as no legitimate consumer product exists at this time.

14.2 Clinical Trial Access

Interested individuals may seek information about future clinical trials through:

· ClinicalTrials.gov

· Revel Pharmaceuticals corporate communications

· Academic medical centers specializing in aging research

14.3 Scientific Literature

Stay informed about CMLase development through peer-reviewed publications and scientific conferences focused on geroscience and protein glycation.

14.4 Distinguishing Legitimate Information

Given the novel nature of CMLase, reliable information sources include:

· Peer-reviewed journals such as Nature Communications

· Official press releases from collaborating institutions

· Presentations at scientific conferences

Be skeptical of commercial claims or products marketed before completion of clinical trials.